Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 12
- Registration Number
- NCT01703364
- Locations
- 🇦🇹
Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III, Salzburg, Austria
🇦🇹Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck, Tirol, Austria
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 78
- Registration Number
- NCT01702831
- Locations
- 🇨🇦
Saint John Regional Hospital, 5DN Research Department, 400 University Ave, Saint John, New Brunswick, Canada
🇨🇦Cross Cancer Institute 11560 University Ave, Edmonton, Alberta, Canada
🇨🇦Queen Elizabeth II Health Sciences Centre., Halifax, Nova Scotia, Canada
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT01698801
- Locations
- 🇯🇵
Iwate Medical University, Morioka, Iwate, Japan
🇯🇵Tokai University Hospital, Isehara, Kanagawa, Japan
🇯🇵National Disaster Medical Center, Tachikawa, Tokyo, Japan
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Gruppo Italiano Studio Linfomi
- Target Recruit Count
- 60
- Registration Number
- NCT01686386
- Locations
- 🇮🇹
U. O. C. Ematologia - Azienda Ospedaliera Cosenza, Cosenza, Italy
Lenalidomide Plus Chemotherapy for AML
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01681537
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Lenalidomide Maintenance Therapy for Multiple Myeloma
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01675141
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Ulsan University Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT01673308
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Conditions
- DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma
- Interventions
- Drug: BortezomibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisBiological: ElotuzumabDrug: Lenalidomide
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 142
- Registration Number
- NCT01668719
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Conditions
- Relapsed or Refractory Systemic Light Chain Amyloidosis
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT01659658
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 32
- Registration Number
- NCT01651039
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.